Clinical trials: Unknown Primary Cancer
Oropharyngeal Cancer, Carcinoma
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph…
- Trial name
- NCT06445114
- Testing
- Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Zachary Zumsteg
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Cancer of Unknown Primary, Bone Cancer Metastatic
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy (platinum + paclitaxel) in the treatment of…
- Conditions
- Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab, Gene Mutation-Related Cancer
- Trial name
- NCT05241132
- Testing
- Tislelizumab plus chemotherapy
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wei Xu
Cancer, CUP
Living Without Answers - ILLUMINATE CUP
This project aims to improve care, service delivery, and patient experience for people with Cancer of Unknown Primary (CUP) by addressing a critical gap in understanding the lived experiences of patients and carers.
- Conditions
- Cancer, CUP, Cancer Unknown Primary
- Trial name
- ILLUMINATE CUP (NCT07712965)
- Volunteers
- 20 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
This early phase I trial studies how well fluciclovine F18 positron emission tomography (PET)/computed tomography (CT) works in identifying the origin of head and neck squamous cell carcinoma in patients with cancer that has…
- Trial name
- NCT03868020
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Cardiac Disease, Dementia
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac…
- Conditions
- Cardiac Disease, Dementia, Inflammatory Disease, Fever of Unknown Origin
- Trial name
- NCT02084147
- Testing
- positron emission tomography, computed tomography, magnetic resonance imaging
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Case Comprehensive Cancer Center
Hematuria - Cause Not Known
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
This study includes adult patients who see a urologist because of blood in their urine. The amount is so small it can only be seen with a microscope. This is called microhematuria. There can be many reasons for microhematuria.
- Trial name
- CREDIBLE (NCT06394869)
- Testing
- Cxbladder Triage Plus
- Where
- 20 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Pacific Edge Limited
Neoplasms, Unknown Primary
Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
The aim of the study is in cancer of unknown primary (CUP) patients, to compare the cost-effectiveness of miRview™ mets test with conventional work-up in identifying the primary tumor site.
- Trial name
- NCT01202786
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Gastric Cancer, Pancreatic Cancer
A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors
The purpose of this study is to establish a neuroendocrine tumor registry. A registry is a collection of information. To create this registry, the investigators would like to get information, blood and tumor samples from people…
- Trial name
- NCT00745381
- Testing
- questionnaire, Blood specimens
- Where
- 3 sites in United States
- Volunteers
- 238 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids…
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site, High-risk Human Papillomavirus Infection, Liquid Biopsy
- Trial name
- NCT05918510
- Testing
- Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
- Where
- Italy
- Volunteers
- 142 people
- Sponsor
- Regina Elena Cancer Institute
Carcinoma of Unknown Primary
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for metastatic cancer of an…
- Trial name
- NCT00022178
- Testing
- cisplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- United Kingdom
- Sponsor
- The Christie NHS Foundation Trust
Breast Carcinoma, Cervical Carcinoma
CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers
This randomized research trial studies the Community-based Health Information Technology (HIT) Tools for Cancer Screening and Health Insurance Promotion (CATCH-UP) intervention in increasing cancer screening and prevention care…
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Health Status Unknown
- Trial name
- NCT02355262
- Testing
- Informational Intervention
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Cervical Cancer Screening, HPV Infection
Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection
The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in…
- Trial name
- NCT07850128
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 130,000 people
- Sponsor
- Karolinska Institutet
Melanoma, Myelodysplastic Syndrome
SCRI Tissue Testing Registry
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients…
- Conditions
- Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Trial name
- NCT00965861
- Testing
- Tissue Registry Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other…
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid
- Trial name
- PUTNET (NCT04276597)
- Testing
- 177Lu-DOTATOC
- Where
- United States
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
Breast Cancer Diagnosis, Breast Cancer Prevention
Contrast Enhanced Mammography in the Evaluation of Cancer of Unknown Primary Syndrome
This study aims to evaluate the role of Contrast-Enhanced Mammography (CEM) in identifying the primary tumor site in patients presenting with Cancer of Unknown Primary (CUP) syndrome.
- Trial name
- CEM_CUP_syndr (NCT06843096)
- Testing
- Contrast-Enhanced Mammography (CEM)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Graziella di Grezia
Carcinoma of Unknown Primary, Head and Neck Cancer
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and…
- Conditions
- Carcinoma of Unknown Primary, Head and Neck Cancer, Non-melanomatous Skin Cancer
- Trial name
- NCT00006361
- Testing
- semaxanib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center